Akari Therapeutics, Plc

AKTX

CT-RANK

CT-Growth

CT-Value

Valuation

Profitability

Fin. Health

Momentum

Stock Performance

Company Information

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Valutazione e Benchmark di Settore

Salute Finanziaria e Fondamentali

Performance Storiche e Volatilità

Profitability and Margins

Efficienza Operativa

Dividendi & Crescita

Per Share Data

Advanced Analysis (AI)

Processing...